1.
Pharmacogenomics
; 24(8): 435-439, 2023 06.
Artículo
en Inglés
| MEDLINE
| ID: mdl-37470120
RESUMEN
Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care.
